Exebacase is a Recombinant Enzyme owned by ContraFect, and is involved in 5 clinical trials, of which 3 were completed, 1 is ongoing, and 1 is planned.

Exebacase elicits antibacterial activity by disrupting bacterial cell wall. Lysins are bacteriophage enzymes that digest the key component of bacteria, the cell wall. When exposed to a lysin the bacterium develops a hole in its wall and due to its internal osmotic pressure it results in lysis.

The revenue for Exebacase is expected to reach a total of $4.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Exebacase NPV Report.

Exebacase was originated by Rockefeller University and is currently owned by ContraFect.

Exebacase Overview

Exebacase (PlySs2) is under development for the treatment of prosthetic joint infections. It is a bacteriophage lysin administered through intravenous and intraarticular route. It is developed based on pAVEway advanced protein expression technology. It was also under development for bacterial pnemonia, abscesses, meningitis and skin structure infections (SSSI) caused by bacteria and staphylococcus bacteremia, including methicillin-resistant S. aureus (MRSA), endocarditis.

ContraFect Overview

ContraFect operates as a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. It develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. The company’s lead product candidates include CF-301, a recombinant bacteriophage derived lysin intended for the treatment of staphylococcus aureus bloodstream infections and offers CF-404, a combination of human monoclonal antibodies intended for the treatment of seasonal and pandemic influenza infections. It’s pipeline portfolio consists other lysin candidates in preclinical stage. ContraFect is headquartered in Yonkers, New York, the US.

The operating loss of the company was US$47.3 million in FY2021, compared to an operating loss of US$34.2 million in FY2020. The net loss of the company was US$20.3 million in FY2021, compared to a net loss of US$28.2 million in FY2020.

Quick View – Exebacase

Report Segments
  • Innovator
Drug Name
  • Exebacase
Administration Pathway
  • Intraarticular
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Infectious Disease
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.